## WST: West Pharmaceutical Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.8% below STRENGTH zone (4.0-10.0%); PEG 3.50 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($263.68)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 2, Bearish: 2)

**1. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Avis Budget, Civitas, Open Lending, and West Pharmaceutical and Encourages Investors to Contact the Firm**
- Source: FOX40 News | 20260101T090851 | Bearish | Relevance: 100%
- Bragar Eagel & Squire, P.C. has filed class action lawsuits against Avis Budget Group, Civitas Resources, Open Lending Corporation, and West Pharmaceutical Services, Inc. Investors are encouraged to contact the firm if they held stock in these companies during the specified class periods. The lawsuits allege that these companies made materially false and misleading statements or failed to disclose crucial information, leading to significant drops in stock prices.

**2. West Pharma’s stock tanks 33% to lead S&P 500 decliners as guidance misses by a wide margin**
- Source: MSN | 20260102T060834 | Bearish | Relevance: 100%
- West Pharmaceutical Services (WST) saw its stock plummet by 33% after issuing preliminary 2024 guidance that fell significantly short of analyst expectations, making it the largest decliner on the S&P 500. The pharmaceutical packaging and delivery company also reported Q4 2023 results that missed revenue forecasts and provided a disappointing revenue outlook for the full year 2024 due to reduced demand in its Biologics segment. This sharp decline has erased nearly $9 billion from its market capitalization.

**3. Cwm LLC Purchases 14,789 Shares of West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20260101T091804 | Bullish | Relevance: 100%
- Cwm LLC significantly increased its stake in West Pharmaceutical Services (NYSE:WST) by 632% in the third quarter, adding 14,789 shares to hold a total of 17,129 shares valued at approximately $4.49 million. West Pharmaceutical Services reported strong Q3 earnings, beating EPS estimates and revenue expectations, and provided optimistic FY2025 guidance. The company maintains a "Moderate Buy" consensus rating from analysts, with several firms raising price targets.

**4. Biotech’s New Edge: 5 Companies Mastering "How" We Dose**
- Source: The Globe and Mail | 20260102T160811 | Bullish | Relevance: 96%
- The pharmaceuticals market is shifting focus from new molecule discovery to advanced drug delivery methods, projected to reach $862.16 billion by 2034. This article highlights five biotech companies—Doseology Sciences Inc., Insulet Corporation, Lipocine Inc., Daré Bioscience, Inc., and West Pharmaceutical Services, Inc.—that are innovating in "how" drugs are delivered, leveraging proprietary platforms for enhanced efficacy and market positioning. These companies are advancing oral stimulants, insulin delivery, postpartum depression treatments, women's sexual health, and prefillable syringe systems, respectively.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.12M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Forward P/E 35.5x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $19.9B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 35.5 |
| Current P/E | 38.9 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.5% to 1.8% (+2.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.2pp (needs >4.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.51), confirming momentum. RSI neutral at 54. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.82% (CS: 68) | Neutral |
| RSI_14 | 53.7 | Neutral |
| MACD Histogram | 0.51 | Bullish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.004x | Above |
| vs SMA200 | 1.137x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $276.40
- **Stop Loss:** $263.68 (4.6% risk)
- **Target:** $289.12 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 113
- **Position Value:** $31,233.20
- **Portfolio %:** 31.23%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*